ENDRA Life Sciences Inc. (NDRA) shareholders
Close on Nov 18, 2026Market cap $6.05MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ASP Isotopes Inc. Joint filing with LHE LNG Holdings LLC (15.10%) | 254,015 | 15.10% | 13D (active) | Oct 1, 2026 |
| Anthony DiGiandomenico | 196,692 | 9.90% | 13D (active) amendment | Jun 25, 2026 |
| Kerry Propper Joint filing with ATW Master Fund V LP (9.90%), ATW Partners Opportunities Management, LLC (9.90%) and 1 more | 116,024 | 9.90% | 13G (passive) | Oct 16, 2025 |
| John Carter Lipman | 115,477 | 9.99% | 13G (passive) | Oct 23, 2025 |
| Salt Rock Capital Partners LLP Joint filing with Salt Rock Master Fund Limited (7.40%) | 110,627 | 7.40% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NDRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Altium Capital Management LP | 59,272 | 3.95% | $315.92K | +7,372 | 0.67% |
| Citadel Advisors LLC | 29,924 | 2.00% | $159.50K | New | 0.00% |
| Citizens Financial Group Inc/Ri | 28,400 | 1.89% | $151.37K | New | 0.00% |
| Geode Capital Management, LLC | 14,910 | 0.99% | $79.47K | −6,168 | 0.00% |
| Vanguard Fiduciary Trust Co | 10,121 | 0.67% | $53.95K | – | 0.00% |
| Vanguard Capital Management LLC | 7,339 | 0.49% | $39.12K | +4,523 | 0.00% |
| Morgan Stanley | 3,546 | 0.24% | $18.90K | – | 0.00% |
| UBS Group AG | 68 | 0.00% | $362 | −84 | 0.00% |
| Tower Research Capital LLC (TRC) | 58 | 0.00% | $309 | New | 0.00% |
| Northwestern Mutual Wealth Management Co | 19 | 0.00% | $101 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 0M | 10.2% | 3 / 2 | 2 / 1 | 0M | 0M |
| Q1 2026 | 8 | 0M | 6.0% | 4 / 1 | 1 / 2 | 0M | 0M |
| Q4 2025 | 7 | 0M | 4.8% | 4 / 1 | 2 / 2 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0.9% | 2 / 0 | 1 / 0 | 0M | 0M |
| Q2 2025 | 3 | 0M | 0.3% | 2 / 1 | 0 / 1 | 0M | 0M |
| Q1 2025 | 2 | 0M | 0.1% | 1 / 0 | 0 / 3 | 0M | 0M |
| Q4 2024 | 4 | 0M | 0.0% | 1 / 2 | 1 / 8 | 0M | 0M |
| Q3 2024 | 11 | 0M | 0.3% | 11 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
3 funds held NDRA in Q2 2026, 31% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NDRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 14,580 | 0.97% | $80.19K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 7,339 | 0.49% | $39.12K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,597 | 0.11% | $8.78K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alexander Y. Tokman | Chief Executive Officer, Director | 101,926 | 6.80% | Mar 4, 2026 |
| Richard Jacroux | Chief Financial Officer | 33,461 | 2.23% | Mar 4, 2026 |
| Anthony Digiandomenico | Director | 136,589 | 9.11% | Jan 23, 2026 |
| Michael Harsh | Director | 65,710 | 4.38% | Jan 23, 2026 |
| Lou Basenese | Director | 65,709 | 4.38% | Jan 23, 2026 |
| Isotopes Inc. ASP | 10% owner | 66,846 | 4.46% | Oct 8, 2026 |
| LNG Holdings LLC LHE | 10% owner | – | – | Oct 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard Jacroux Chief Financial Officer | Mar 2, 2026 | Award | +13,461 | – | – | 33,461 |
| Alexander Y. Tokman Chief Executive Officer, Director | Mar 2, 2026 | Award | +26,921 | – | – | 101,926 |
| Anthony Digiandomenico Director | Jan 21, 2026 | Award | +60,324 | – | – | 136,589 |
| Richard Jacroux Chief Financial Officer | Jan 21, 2026 | Award | +20,000 | – | – | 20,000 |
| Alexander Y. Tokman Chief Executive Officer, Director | Jan 21, 2026 | Award | +75,000 | – | – | 75,005 |
| Lou Basenese Director | Jan 21, 2026 | Award | +60,324 | – | – | 65,709 |
| Michael Harsh Director | Jan 21, 2026 | Award | +60,324 | – | – | 65,710 |
| Anthony Digiandomenico Director | Oct 10, 2025 | Award | +70,822 | $7.06 | $500.00K | 76,265 |
| Anthony Digiandomenico Director | Jun 11, 2025 | Award | +5,384 | – | – | 5,443 |
| Michael Harsh Director | Jun 11, 2025 | Award | +5,384 | – | – | 5,386 |
| Lou Basenese Director | Jun 11, 2025 | Award | +5,384 | – | – | 5,385 |
| Group AG UBS – | Aug 27, 2024 | Buy | +0 | – | – | 146,012 |
| Group AG UBS 10% owner | Aug 27, 2024 | Buy | +3,715 | $0.55 | $2.04K | 146,012 |
| Michael Milos Thornton Chief Technology Officer | May 18, 2023 | Buy | +15,000 | $1.65 | $24.75K | 34,139 |
| Anthony Digiandomenico Director | May 2, 2023 | Buy | +83,333 | $1.20 | $100.00K | 102,434 |
| Michael Milos Thornton Chief Technology Officer | Dec 9, 2022 | Buy | +1,500 | $3.40 | $5.10K | 19,139 |
| Alexander Y. Tokman Director | Nov 23, 2022 | Buy | +10,000 | $0.17 | $1.70K | 162,857 |
| Alexander Y. Tokman Director | Aug 22, 2022 | Buy | +20,000 | $0.26 | $5.20K | 152,857 |
| Michael Milos Thornton Chief Technology Officer | Aug 22, 2022 | Buy | +20,000 | $0.27 | $5.40K | 352,775 |
| Michael Milos Thornton Chief Technology Officer | May 26, 2022 | Buy | +25,000 | $0.21 | $5.25K | 332,775 |
| Michael Milos Thornton Chief Technology Officer | May 18, 2022 | Buy | +25,000 | $0.22 | $5.50K | 307,775 |
| Francois Roger Michelon Chief Executive Officer, Director | May 17, 2022 | Buy | +5,100 | $0.19 | $969 | 97,191 |
| Alexander Y. Tokman Director | May 16, 2022 | Buy | +100,000 | $0.20 | $20.00K | 132,857 |
| Lou Basenese Director | Aug 26, 2021 | Sale | −5,000 | $1.85 | $9.25K | 49,068 |
| Lou Basenese Director | Aug 25, 2021 | Sale | −45,000 | $1.83 | $82.35K | 54,068 |
| Michael Milos Thornton Chief Technology Officer | Apr 7, 2021 | Sale(10b5-1 plan) | −15,000 | $2.53 | $37.95K | 259,960 |
| Michael Milos Thornton Chief Technology Officer | Mar 29, 2021 | Sale(10b5-1 plan) | −18,750 | $2.37 | $44.44K | 274,960 |
| Michael Milos Thornton Chief Technology Officer | Feb 11, 2021 | Award | +22,815 | – | – | 316,525 |
| Michael Milos Thornton Chief Technology Officer | Jan 28, 2021 | Award | +22,815 | – | – | 316,525 |
| Renaud Bertrand Maloberti Chief Commercial Officer | Jan 13, 2021 | Sale(10b5-1 plan) | −13,696 | $1.10 | $15.07K | 1,580 |
| Renaud Bertrand Maloberti Chief Commercial Officer | Jan 12, 2021 | Sale(10b5-1 plan) | −6,304 | $1.05 | $6.62K | 15,276 |
| Alexander Y. Tokman Director | Jan 8, 2021 | Sale(10b5-1 plan) | −10,000 | $0.90 | $9.00K | 32,857 |
| Renaud Bertrand Maloberti Chief Commercial Officer | Jan 8, 2021 | Sale(10b5-1 plan) | −8,731 | $0.94 | $8.21K | 21,580 |
| Renaud Bertrand Maloberti Chief Commercial Officer | Jan 6, 2021 | Sale(10b5-1 plan) | −11,269 | $0.94 | $10.59K | 30,311 |
| David R. Wells Chief Financial Officer | Jan 6, 2021 | Sale(10b5-1 plan) | −34,900 | $0.90 | $31.41K | 80,003 |
| David R. Wells Chief Financial Officer | Jan 5, 2021 | Sale(10b5-1 plan) | −100 | $0.90 | $90 | 114,903 |
| Renaud Bertrand Maloberti Chief Commercial Officer | Dec 17, 2020 | Sale(10b5-1 plan) | −25,000 | $0.73 | $18.25K | 41,580 |
| Francois Roger Michelon Chief Executive Officer, Director | Dec 4, 2020 | Sale(10b5-1 plan) | −71,519 | $0.83 | $59.36K | 92,091 |
| Renaud Bertrand Maloberti Chief Commercial Officer | Nov 13, 2020 | Sale(10b5-1 plan) | −10,000 | $0.81 | $8.10K | 66,580 |
| Renaud Bertrand Maloberti Chief Commercial Officer | Oct 1, 2020 | Sale(10b5-1 plan) | −10,000 | $0.72 | $7.20K | 76,580 |
| Anthony Digiandomenico Director | Jul 21, 2020 | Option exercise | +100,503 | $0.87 | $87.44K | 382,012 |
| Michael Milos Thornton Chief Technology Officer | Jul 15, 2020 | Option exercise | +26,000 | $0.87 | $22.62K | 293,710 |
| David R. Wells Chief Financial Officer | Jun 23, 2020 | Option exercise | +5,000 | $0.87 | $4.35K | 115,003 |
| Michael Harsh Director | Jun 23, 2020 | Option exercise | +5,000 | $0.87 | $4.35K | 69,243 |
| Francois Roger Michelon Chief Executive Officer, Director | Jun 23, 2020 | Option exercise | +2,874 | $0.87 | $2.50K | 163,610 |
| Francois Roger Michelon Chief Executive Officer, Director | Jun 8, 2020 | Conversion | +5,175 | $0.87 | $4.50K | 160,736 |
| Michael Harsh Director | Jun 8, 2020 | Conversion | +11,386 | $0.87 | $9.91K | 64,243 |
| Michael Milos Thornton Chief Technology Officer | Jun 8, 2020 | Conversion | +51,747 | $0.87 | $45.02K | 267,710 |
| David R. Wells Chief Financial Officer | Jun 8, 2020 | Conversion | +10,350 | $0.87 | $9.00K | 110,003 |
| Anthony Digiandomenico Director | Jun 8, 2020 | Buy | +5,000 | $0.92 | $4.60K | 281,509 |
| Lou Basenese Director | May 29, 2020 | Buy | +10,000 | $0.90 | $9.00K | 99,068 |
| Lou Basenese Director | May 28, 2020 | Buy | +10,000 | $0.91 | $9.10K | 89,068 |
| Anthony Digiandomenico Director | May 28, 2020 | Buy | +5,000 | $0.90 | $4.50K | 276,509 |
| Lou Basenese Director | May 27, 2020 | Buy | +10,000 | $0.85 | $8.50K | 79,068 |
| Lou Basenese Director | May 26, 2020 | Buy | +10,000 | $0.82 | $8.20K | 69,068 |
| Anthony Digiandomenico Director | May 22, 2020 | Buy | +10,000 | $0.78 | $7.80K | 252,083 |
| Lou Basenese Director | May 21, 2020 | Buy | +10,000 | $0.71 | $7.10K | 59,068 |
| Lou Basenese Director | Apr 9, 2020 | Award | +41,587 | – | – | 41,587 |
| Michael Milos Thornton Chief Technology Officer | Apr 9, 2020 | Award | +96,213 | – | – | 215,963 |
| Anthony Digiandomenico Director | Apr 9, 2020 | Award | +42,857 | – | – | 242,083 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ENDRA Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,941 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Anthony Digiandomenico Board Member | Jun 25, 2026 | 70,822 | $425.00K | Jun 26, 2026 | Private Placement |
See a number that looks wrong?